NXS 6.25% 25.5¢ next science limited

Revenue growth 31% vs. Operating Expense growth of +33%, with...

  1. 268 Posts.
    lightbulb Created with Sketch. 125
    Revenue growth 31% vs. Operating Expense growth of +33%, with Judith saying she's hiring 10 more sales reps this April and would like to do this at least 2 to 3 times more this year alone, basically the partnerships have been a disaster. Right now there is no operating leverage in this business meaning even if top line grows the losses only grows with it (if not accelerate), cash burn will continue with management having no intention of reaching cashflow breakeven (not mentioned at all in the presentation). Finally as mentioned no one wants to take up the CEO role which is another growing concern. Think I'm happy to let Walker continue to fund this money pit for now...
 
watchlist Created with Sketch. Add NXS (ASX) to my watchlist
(20min delay)
Last
25.5¢
Change
0.015(6.25%)
Mkt cap ! $74.50M
Open High Low Value Volume
25.0¢ 26.0¢ 24.5¢ $47.92K 186.1K

Buyers (Bids)

No. Vol. Price($)
1 7885 25.5¢
 

Sellers (Offers)

Price($) Vol. No.
26.0¢ 72561 2
View Market Depth
Last trade - 15.57pm 19/08/2024 (20 minute delay) ?
NXS (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.